How many clinical trials are studying Sodium Bicarbonate?

3 recruiting trials in our tracked data involve Sodium Bicarbonate.

What conditions is Sodium Bicarbonate being studied for?

In our tracked recruiting trials, Sodium Bicarbonate is being studied in trials for Chronic Kidney Disease, Chronic Kidney Diseases, Diabetes.

Yes. According to the FDA drug label available through openFDA, Sodium Bicarbonate is an FDA-approved drug. Its FDA label carries a boxed warning.

Recruiting trials

Conditions studied

US states with sites

Countries

FDA-approved: Yes. Sodium Bicarbonate appears in the FDA drug-label database. Marketed as Sodium Bicarbonate.
Boxed warning: The FDA label for Sodium Bicarbonate carries a boxed warning (the FDA's most serious warning). See the full label for details.

Uses: relieves • acid indigestion • heartburn • sour stomach • upset stomach associated with these symptoms

Reason (FDA)	Classification	Status	Initiated
cGMP deviations: Temperature abuse — Mckesson Medical-Surgical Inc. Corporate Office	Class II (FDA: may cause temporary or reversible harm)	Terminated	2022-04-13
Lack of Assurance of Sterility — Exela Pharma Sciences LLC	Class II (FDA: may cause temporary or reversible harm)	Ongoing	2025-03-07
Presence of Particulate Matter: Silicone — Exela Pharma Sciences LLC	Class I (FDA: reasonable probability of serious harm or death)	Ongoing	2023-10-18
Labeling Not Elsewhere Classified; orange and cherry flavor packets incorrect list "natural lemon flavor" as an ingredient — LUPIN SOMERSET	Class II (FDA: may cause temporary or reversible harm)	Terminated	2019-03-19
Failed Stability Specification; Out of specification for Osmolarity — Novel Laboratories, Inc. d.b.a LUPIN	Class II (FDA: may cause temporary or reversible harm)	Terminated	2021-07-29

Phase 1 1 Phase 2 2

Condition	Trials
Chronic Kidney Disease · Sodium Bicarbonate for Chronic Kidney Disease	3
Chronic Kidney Diseases	1
Diabetes	1
Fatigue	1
Insulin Resistance	1
Metabolic Acidosis	1
Mitochondrial Energetics	1
Physical Endurance	1

Neurovascular Regulation During Exercise in Humans With Chronic Kidney Disease: Sympatholysis in CKD
NCT05928936 · Phase: Phase 2 · Ages: 40 Years to 75 Years · Sex: All (male and female) · 2 locations
Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD
NCT04984226 · Phase: Phase 2 · Ages: 21 Years to 85 Years · Sex: All (male and female) · 2 locations
Sympatholysis in Chronic Kidney Disease
NCT02411773 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location

Yes, marketed as Sodium Bicarbonate. Its FDA label carries a boxed warning.

3 recruiting trials across 8 conditions.

No. For the full record, search ClinicalTrials.gov.